MedTrace Logo

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

NCT00313768 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2009-09-28

No results posted yet for this study

Summary

To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

paclitaxel + carboplatin + bevacizumab

paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles

DRUG

carboplatin + paclitaxel + bevacizumab + PF-3512676

carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00313768 on ClinicalTrials.gov